Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Laser Photonics Seeks Approval for Laser Treatment of Psoriasis

Facebook Twitter LinkedIn Email Comments
CARLSBAD, Calif., Sept. 1 -- Laser Photonics Inc. announced that its Acculase Inc. subsidiary has filed with the US Food and Drug Administration for 510 (k) clearance to commercially market its excimer laser system for the treatment of dermatological disorders, including psoriasis. The company expects to launch the product in early 2000, and has engaged Healthworld Corp. to handle advertising, contract sales, consulting, medical education, public relations and marketing research.
Laser Photonics recently completed a financing to fund capital expenditures related to marketing activities and to additional clinical trials, which are being conducted at Massachusetts General Hospital. The company said its excimer laser is designed to use fiber optics to deliver UV energy precisely to lesion sites, thereby minimizing the effects of treatment on non-affected skin.

Photonics.com
Sep 1999
News & Featureslasers

Comments
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.